Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigatinib and Binimetinib in Advanced ALK- or ROS1-Rearranged NSCLC
NCT04005144Phase 1Terminated
- Sponsor
- University of California, San Francisco
- Start
- Feb 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of binimetinib in non-small cell lung carcinoma (NSCLC), sponsored by University of California, San Francisco. Primary endpoints: Recommended Phase 2 Dose up to 12 months, Number of Participants with Dose Limiting Toxicities up to 28 days and 1 more. Started Feb 2020; status: terminated.
02
Drugs
binimetinib
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT04005144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04005144.